A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the
efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
The objective of this study is to evaluate the efficacy, safety and tolerability of
sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change
from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk
distance (6MWD, key secondary endpoint).